Placeholder Banner

PASTEUR Act is Promising Bipartisan Reform, Will Strengthen Antimicrobial Development

June 16, 2021
Media Contact
Vicky Stinson
202-962-6660

Today, Congress introduced the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, which proposes a new approach to drive increased private sector investment & improve financial stability in the market for antibiotic research and development.

The bill was introduced in the U.S. Senate by Senators Michael Bennet (D-CO) and Todd Young (R-IN) and in the U.S. House by Representatives Mike Doyle (D-PA) and Drew Ferguson (R-GA).

Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the bill’s introduction:

"Antimicrobial resistance is an urgent public health threat in the United States and around the world. For years, we have seen the number of drug-resistant infections rise while the number of new antibiotics available to fight them drop. Today, Congress has taken an important first step to address this crisis and present a critical public health tool that will help save lives and bring novel innovations to patients.

“I commend U.S. lawmakers for their leadership in taking an important step forward to help tackle this global public health challenge. BIO looks forward to working with lawmakers to continue to strengthen this legislation and other promising bipartisan reforms that will help deliver more innovative antimicrobial medicines to patients.”

###

Discover More
WASHINGTON – BIO President & CEO John F. Crowley released the following statement on the results of the 2024 U.S. election:“We look forward to working closely with President-elect Trump, his incoming Administration, and members of Congress on…
The Biotechnology Innovation Organization (BIO) is proud to announce that industry leader and military veteran John F. Crowley will be its new President and CEO, effective March 4. He will replace Rachel King, a longtime BIO board member and…
Biotechnology companies are hard at work on the cutting-edge innovations we need, but those breakthroughs are at risk from current tax policy. The Biotechnology Innovation Organization, which represents more than 1,000 biotech companies, thanks…